Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cleistanthin A is a naturally occurring arylnaphthalide lignan glycoside isolated primarily from the plant Cleistanthus collinus. It is one of the toxic principles of this plant and has been studied for its pharmacological activities including antihypertensive effects (alpha adrenergic antagonism), diuretic action, and potential anticancer properties. Mechanistically, cleistanthin A acts as a noncompetitive antagonist at alpha‑adrenergic receptors (notably α₁), leading to vasodilatory effects. It also exhibits anti-inflammatory and antioxidant activities and has shown efficacy in preclinical models for reducing benign prostatic hyperplasia by downregulating inflammatory pathways (such as IL‑6/STAT‑3/cyclin D1) and inducing apoptosis in target tissues[1][4][7][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cleistanthin a.